Medicago Shut Down: COVID-19 Vaccine Competition Among Reasons

$364m Impairment Loss For Mitsubishi

 
• By Lisa Takagi
  
Medicago had been facing several challenges with its COVID-19 vaccine COVIFENZ
Medicago faced multiple challenges for lead vaccine Covifenz • Source: Shutterstock

More from Business

More from Scrip